Description
This compound is a novel synthetic peptide engineered to act as a triagonist at the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors. This triple receptor engagement represents an emerging area of metabolic research, with preclinical and early clinical studies investigating its effects on energy expenditure, hepatic lipid metabolism, glycemic regulation, and adipose tissue dynamics. The addition of glucagon receptor agonism to the incretin framework is hypothesized to enhance thermogenic and lipolytic effects. This 10mg lyophilized preparation is intended strictly for in vitro research and laboratory investigation. Not for human consumption.
